RxDoctor Payments Data

Jose Valle, MD

Internal Medicine · Marshall, MINPI 1649227604

Payments from drug & device makers

$248in general payments, 2019–2025

Across 17 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$45
  • Astellas Pharma US Inc$36
  • Amgen$29
  • Pfizer$27
  • Boehringer Ingelheim$23
  • GSK$19
  • plus $69 from 5 others

What the payments were for

  • Food & beverage$248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$248 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$146,494
Medicare patients
349
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$282,434
JanuviaSitagliptin Phosphate111$109,826
XareltoRivaroxaban98$92,367
MyrbetriqMirabegron81$69,136
JardianceEmpagliflozin73$54,843
FarxigaDapagliflozin Propanediol35$32,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$30,813
InvokanaCanagliflozin34$25,429
OzempicSemaglutide19$23,219
Bydureon BciseExenatide Microspheres21$21,559
TrulicityDulaglutide12$20,214
RybelsusSemaglutide17$19,687
Atorvastatin Calcium1,217$16,483
EntrestoSacubitril/Valsartan14$16,449
Spiriva HandihalerTiotropium Bromide12$15,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$27$290,668297 claims
Johnson & JohnsonXarelto, Invokana$45$117,795132 claims
MerckJanuvia$11$109,826111 claims
Astellas Pharma US IncMyrbetriq$36$69,13681 claims
Boehringer IngelheimJardiance, Tradjenta$23$67,31599 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$19$56,15692 claims
Novo NordiskOzempic, Rybelsus$14$42,90736 claims
NovartisEntresto$15$16,44914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Marshall

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →